United Therapeutics Net Change in Cash decreased by 9.6% to -$277.40M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 236.9%, from $202.70M to -$277.40M. Over 3 years (FY 2021 to FY 2024), Net Change in Cash shows an upward trend with a 42.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
A positive change indicates net cash generation, while a negative change indicates cash consumption for the period.
The total net increase or decrease in cash, cash equivalents, and restricted cash during the reporting period. It is the...
A fundamental liquidity metric used to compare cash management efficiency across all public companies.
net_change_in_cash| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $109.90M | -$33.70M | $0.00 | -$81.50M | -$18.10M | $171.60M | $0.00 | $202.30M | -$96.20M | $40.40M | $100.00M | $43.80M | $104.20M | $198.20M | $143.30M | $202.70M | -$306.80M | -$253.00M | -$277.40M |
| QoQ Change | — | -130.7% | +100.0% | — | +77.8% | >999% | -100.0% | — | -147.6% | +142.0% | +147.5% | -56.2% | +137.9% | +90.2% | -27.7% | +41.5% | -251.4% | +17.5% | -9.6% |
| YoY Change | — | — | — | — | -116.5% | +609.2% | — | +348.2% | -431.5% | -76.5% | — | -78.3% | +208.3% | +390.6% | +43.3% | +362.8% | -394.4% | -227.6% | -236.9% |